Mml Investors Services, LLC Galectin Therapeutics Inc Transaction History

Mml Investors Services, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $726 - $1,144	-550 Reduced 1.0%	54,227 $78,000
Q4 2022 Feb 13, 2023	BUY	$1.03 - $1.66 $5,150 - $8,300	5,000 Added 10.04%	54,777 $62,000
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.48 $14,410 - $27,280	11,000 Added 28.37%	49,777 $81,000
Q1 2022 May 13, 2022	BUY	$1.61 - $2.31 $8,050 - $11,550	5,000 Added 14.8%	38,777 $62,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $6,125 - $11,244	2,959 Added 9.6%	33,777 $70,000
Q4 2020 Feb 12, 2021	BUY	$2.24 - $2.87 $5,100 - $6,534	2,277 Added 7.98%	30,818 $69,000
Q1 2020 May 14, 2020	BUY	$1.51 - $3.0 $9,664 - $19,200	6,400 Added 28.91%	28,541 $55,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.05 $19,956 - $26,940	-6,652 Reduced 23.1%	22,141 $81,000
Q2 2019 Aug 13, 2019	BUY	$3.61 - $5.0 $28,912 - $40,045	8,009 Added 38.53%	28,793 $119,000
Q1 2019 May 10, 2019	SELL	$3.86 - $6.02 $23,708 - $36,974	-6,142 Reduced 22.81%	20,784 $106,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $33,072 - $55,345	9,642 Added 55.79%	26,926 $92,000
Q3 2018 Nov 07, 2018	SELL	$3.68 - $6.93 $11,875 - $22,363	-3,227 Reduced 15.73%	17,284 $104,000
Q2 2018 Aug 13, 2018	BUY	$3.16 - $9.16 $9,217 - $26,719	2,917 Added 16.58%	20,511 $130,000
Q1 2018 May 11, 2018	SELL	$3.78 - $5.97 $36,359 - $57,425	-9,619 Reduced 35.35%	17,594 $83,000
Q4 2017 Feb 13, 2018	BUY	$1.54 - $3.34 $24,365 - $52,845	15,822 Added 138.9%	27,213 $91,000
Q3 2017 Nov 14, 2017	BUY	$1.67 - $2.3 $19,022 - $26,199	11,391	11,391 $24,000

10M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.1M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Mml Investors Services, LLC with notifications on news.